Keyphrases
Chronic Obstructive Pulmonary Disease
89%
Respiratory Outcomes
49%
Omadacycline
48%
Former Smokers
42%
Mouse Model
34%
Disease Morbidity
34%
Mycobacteroides Abscessus
33%
SPIROMICS
32%
Mycobacterium Abscessus
30%
Imipenem
26%
Linezolid
26%
Exacerbation Risk
25%
Lung Disease
23%
Confidence Interval
22%
Amikacin
21%
Clofazimine
21%
Respiratory Symptoms
20%
Neighborhood Deprivation
19%
Severe Exacerbations
18%
Respiratory Morbidity
18%
Current Smokers
17%
Specific Quality of Life
17%
Indoor Air Pollution
17%
Chronic Obstructive Pulmonary Disease Assessment Test
17%
St. George's Respiratory Questionnaire
16%
Mycobacterium Avium Complex Pulmonary Disease
16%
Neighborhood Factors
16%
Patient-reported Health
16%
Health-related Quality of Life
16%
Three-level
16%
Racial Disparities
16%
Indoor Particulate Matter
16%
Three-drug Regimen
16%
Patient-reported Symptoms
16%
Food Insecurity
16%
Lung Function Decline
16%
Omega-3
16%
Pollution Function
16%
Eicosapentaenoic Acid
16%
Ozone Effect
16%
Smokers
16%
Black Residents
16%
Perceived Stress
16%
Racial Segregation
16%
FEV1 Decline
16%
Phthalates
16%
Ambient Ozone
16%
All-oral Regimen
16%
Anaemia Status
16%
Anaemia Risk
16%
Medicine and Dentistry
Chronic Obstructive Pulmonary Disease
100%
Smoking
69%
Quality of Life
35%
Atmospheric Aerosol
32%
Symptom
27%
Socioeconomic Status
17%
Racial Disparity
16%
Biological Marker
16%
Icosapentaenoic Acid
16%
Mycobacterium Avium Complex
16%
Omega-3 Fatty Acid
16%
Silo-Filler's Disease
16%
Lung
16%
Adverse Outcome
16%
Anemia
16%
Docosahexaenoic Acid
14%
Medical Research
12%
Dyspnea
12%
Respiratory Physiology
10%
St. George Respiratory Questionnaire
9%
Health Outcomes
8%
Mixed Model
8%
Disease Assessment
7%
Six Minute Walk Test
7%
Emphysema
7%
Air Trapping
7%
Bronchiectasis
6%
Computer Assisted Tomography
6%
Particular Matter 2.5
5%
Forced Expiratory Volume
5%
Adverse Event
5%
Respiratory System Disease
5%
Body Mass Index
5%
Cohort Analysis
5%
Spirometry
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Obstructive Lung Disease
82%
Lung Disease
36%
Mouse Model
32%
Omadacycline
32%
Disease
24%
Imipenem
20%
Linezolid
20%
Amikacin
18%
Clofazimine
18%
Biological Marker
17%
Symptom
17%
Phthalic Acid
16%
Mycobacterium Avium Complex
16%
Mixed Model
9%
Bronchiectasis
8%
Nitrogen Dioxide
8%
Disease Exacerbation
8%
Antibiotic Agent
5%
